Elite LGD 4033 [Discontinued] by Focused Nutrition Europe

INSUFFICIENT RELIABLE EVIDENCE to RATE

• Athletic performance. Although there is interest in using oral ligandrol for athletic performance, there is insufficient reliable information about the clinical effects of ligandrol for this purpose.
• Breast cancer. Although there is interest in using oral ligandrol for breast cancer, there is insufficient reliable information about the clinical effects of ligandrol for this condition.
• Cachexia. Although there is interest in using oral ligandrol for cachexia, there is insufficient reliable information about the clinical effects of ligandrol for this condition.
• Muscle strength. It is unclear if oral ligandrol is beneficial for increasing muscle strength. Details: A small and preliminary clinical trial shows that taking ligandrol 0.1, 0.3, or 1.0 mg daily for 3 weeks does not improve muscle strength when compared with placebo (113951). However, the study may have been inadequately powered to detect a difference between groups.
• Muscular dystrophy. Although there is interest in using oral ligandrol for muscular dystrophy, there is insufficient reliable information about the clinical effects of ligandrol for this condition.
• Sarcopenia. Although there is interest in using oral ligandrol for sarcopenia, there is insufficient reliable information about the clinical effects of ligandrol for this condition.
• Urinary incontinence. Although there is interest in using oral ligandrol for urinary incontinence, there is insufficient reliable information about the clinical effects of ligandrol for this condition. More evidence is needed to rate ligandrol for these uses.

(Read more about LIGANDROL)

POSSIBLY UNSAFE ...when used orally or parenterally. Ligandrol 0.1-1.0 mg daily has been used with apparent safety under medical supervision for up to 3 weeks in clinical research (113951). However, there are concerns about the potential of ligandrol and other selective androgen receptor modulators (SARMs) to cause serious adverse reactions, including hepatotoxicity, myocardial infarction, and stroke (94879,94880,94881). There are case reports of liver injury associated with use of ligandrol (108160,112650,112682,112683). The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing SARMs are dangerous (91094).

PREGNANCY AND LACTATION: POSSIBLY UNSAFE
when used orally or parenterally. The U.S. Food and Drug Administration and other regulatory agencies warn that dietary supplements containing selective androgen receptor modulators (SARMs) are dangerous (91094). Avoid using.

(Read more about LIGANDROL)

HEPATOTOXIC DRUGS Interaction Rating = Moderate Be cautious with this combination. Severity = High •  Occurrence = Possible •  Level of Evidence = D Theoretically, concomitant use might have additive hepatotoxic effects.  Details In case reports, patients were diagnosed with liver injury thought to be related to the use of products containing ligandrol (108160,112650,112682,112683).

(Read more about LIGANDROL)

General ...Orally, ligandrol is possibly unsafe.
Serious Adverse Effects (Rare):
Orally: Hepatotoxicity.

Cardiovascular ...Orally, ligandrol 0. 3 mg or 1.0 mg daily for 3 weeks has resulted in a decrease in high-density lipoprotein (HDL) cholesterol levels (113951).

Hepatic ...There are cases of liver injury thought to be related to the use of ligandrol alone or in combination with other SARMs. The U.S. Food and Drug Administration (FDA) has warned that supplements containing SARMs, such as ligandrol, have been associated with liver toxicity (94879,94880,94881).
There are at least 3 cases of liver injury thought to be related to the use of ligandrol alone (112650,112682,112683). In one case report, a 32-year-old male used ligandrol 10 mg daily for 2 weeks. Soon after, he developed symptoms of elevated liver enzymes, jaundice, pruritus, fatigue, abdominal pain, and weight loss. These symptoms continued for approximately 2 months before diagnosis of severe drug-induced liver injury thought to be associated with ligandrol (112650). In another case, a 19-year-old male was hospitalized with jaundice with elevated liver enzymes associated with a mild mixed-type drug-induced liver injury following the use of an unknown amount of ligandrol daily for 7 weeks over an 11-week period. Liver enzymes returned to normal following treatment with ursodeoxycholic acid daily for 2 months (112682). It is unclear if these cases were due to unapproved substance(s) not reported on the label. In a third case, a 24-year-old male also developed jaundice, along with elevated liver enzymes, nausea, lethargy, and appetite and weight loss following the use of ligandrol for 9 weeks. His liver enzymes normalized after 4 months. No contaminants were identified in this product (112683).
Liver injury has also occurred in case reports of individuals taking ligandrol in combination with other SARMs or anabolic steroids. In a 52-year-old male, liver injury thought to be related to the use of testolone 20 mg daily (Alpha Bolic) for 4 weeks and then testolone 15 mg daily with ligandrol 10 mg daily (Alpha Elite) for 3 weeks occurred. The patient presented with elevated liver enzymes, jaundice, pruritus, diarrhea, and upper right quadrant pain; liver enzymes were significantly improved 3 months after cessation of the supplements and alcohol intake (108160). In another case of a 24-year-old male, a mixed-type drug-induced liver injury occurred after taking ligandrol and ostarine daily for 3 months, followed by taking 6 pills of a specific product (Spartan) containing anabolic steroids (112682). However, it is unclear if these cases of liver injury were due to ligandrol, the other ingredients, the combination, unapproved substance(s) not reported on the label, and/or alcohol use.

(Read more about LIGANDROL)